Subset analysis of patients with sarcomatoid renal cell carcinoma (sRCC) included in the CheckMate 214 trial of ipilimumab-nivolumab versus sunitinib showed improved outcomes in sRCC with ipilimumab-nivolumab. The use of checkpoint inhibitor–based regimens in sRCC, for which therapeutic options were once limited, is further supported by additional clinical trials.
|Original language||English (US)|
|Number of pages||3|
|Journal||Clinical Cancer Research|
|State||Published - Jan 1 2021|
ASJC Scopus subject areas
- Cancer Research